Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5740)
All Articles published online
|
Publishing Process of This Article
|
Feb 16, 2021 (publication date) through May 7, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wong-Chong J, Bernadach M, Ginzac A, Veyssière H, Durando X. Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report. World J Clin Cases 2021; 9(5): 1139-1147 [PMID: 33644178 DOI: 10.12998/wjcc.v9.i5.1139] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v9/i5/1139.htm |
| Number | Citing Articles |
| 1 |
Yi-Fan Jiang, Jian Wu, Di-Yu Chen. A rare case of thymic carcinoma metastasize to liver. Hepatobiliary & Pancreatic Diseases International 2025; 24(2): 217 doi: 10.1016/j.hbpd.2023.12.003
|
| 2 |
|
| 3 |
Yoichi Nishii, Kazuki Furuhashi, Kentaro Ito, Tadashi Sakaguchi, Yuta Suzuki, Kentaro Fujiwara, Taro Yasuma, Tetsu Kobayashi, Corina N. D’Alessandro-Gabazza, Esteban C. Gabazza, Osamu Taguchi, Osamu Hataji. Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report. Pharmaceuticals 2022; 15(7): 889 doi: 10.3390/ph15070889
|